Press Releases

Jun 17, 2026

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Jun 15, 2026

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

May 19, 2026

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

May 11, 2026

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Apr 27, 2026

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Mar 30, 2026

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 03, 2026

Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference

Feb 05, 2026

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February

Jan 27, 2026

Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics

Jan 12, 2026

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy